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Aims: To undertake a questionnaire-based study to evaluate attitudes towards the use of 
un  licensed medicines among prescribing doctors and members of the general public (ie, 
patients). The study also aimed to explore the factors that influence physicians’ prescribing 
decisions and priorities, and to understand the knowledge of the medicines licensing system 
among members of the public.
Methods: Novartis Pharmaceuticals UK Ltd funded the online interview of 500 members 
of the general public and 249 prescribing physicians. Best practice standards were followed 
for questionnaire-based studies; no specific treatments or conditions were mentioned or 
discussed.
Results: Few of the participating physicians, only 14%, were very familiar with the UK General 
Medical Council (GMC) guidelines on the use of unlicensed medicines and just 17% felt very 
comfortable prescribing an unlicensed medication when a licensed alternative was available. 
Key physician concerns included the lack of safety data (76%), legal implications (76%), and 
safety monitoring associated with unlicensed medicine use (71%). Patients and physicians 
agreed that safety and efficacy are the most important prescribing considerations, although 
48% of participating physicians were worried that budget pressures may increase pressure to 
prescribe unlicensed medications on the basis of cost. A high proportion of patients (81%) also 
indicated some degree of concern, were they to be prescribed an unlicensed medication when 
a licensed alternative was available specifically because it costs less.
Conclusions: This UK-based questionnaire study suggests pervasive concerns among prescrib-
ers over the safety, monitoring, and legal implications of unlicensed prescribing. High levels 
of concern were expressed among patients and physicians if cost were to become an influential 
factor when making decisions between licensed and unlicensed medications.
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Introduction
The UK’s General Medical Council (GMC) recently issued for consultation draft 
guidance relaxing their stance on the use of unlicensed medicines. This proposed 
revised position comes at a time of increased budgetary pressures within the National 
Health Service (NHS) leading to concerns over increasing pressures to prescribe 
cheaper therapies irrespective of their license status or the availability of robust safety 
and efficacy data. Indeed, the UK Department of Health plans to commission expert 
assessments of the evidence for the use of off-label drugs in the light of estimates that 
around 1000 specific requests for off-label drug use are made to NHS commissioners 
in England every year.
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The GMC’s existing guidance states that an unlicensed 
medicine should not be prescribed where a licensed alterna-
tive is available.1 In contrast, the proposed, new guidance 
affords physicians greater discretion, allowing them to 
prescribe off-label, or unlicensed, drugs if no appropriate 
licensed alternative is available, or if they are satisfied that the 
unlicensed option is as safe and efficacious.2 Irrespective of 
the change in guidance, physicians are still required to have 
adequate insurance or indemnity cover should they choose 
to prescribe unlicensed drugs.2 The legal responsibility for 
the outcome of an unlicensed drug prescription (and patient’s 
aftercare) still resides with the prescriber.
An “unlicensed medicinal product” is one that has not 
been evaluated by a competent regulatory authority as hav-
ing an appropriate risk:benefit profile because no regulatory 
submission has been prepared and considered. There are 
liabilities that should be considered by all those involved 
in the prescribing of medicines, ranging from obligations 
under professional codes of conduct to common law (eg, 
negligence) and statutory obligations and liabilities under 
Consumer Protection legislation.3
The draft GMC guidance was published shortly after 
new Quality Outcome Framework (QoF) indicators were 
introduced, which encourage general practitioners (GPs) to 
make efficiency savings in prescribing.4 The new QoF targets 
require practices to review their current prescribing behavior 
to assess its clinical and cost effectiveness. Three areas of 
improvement must be identified and agreed with the Primary 
Care Organisation and subsequent payments will be made in 
line with the percentage of prescriptions issued in the first 
quarter of 2012 that comply with each of three agreed plans. 
Against this backdrop, the relaxation of the GMC guidance 
on unlicensed prescribing may see physicians coming under 
increased pressure to prescribe cheaper therapies, irrespective 
of their license status.
To obtain a marketing authorization, drug manufacturers 
must carry out extensive, costly trials to satisfy regulatory 
bodies (ie, the European Medicines Agency [EMA] in Europe 
and the Food and Drug Administration [FDA] in the US) of 
the medicine’s positive safety profile and efficacy compared 
to existing gold standard therapy. Furthermore, as part of 
the submission, the manufacturer must also demonstrate an 
optimal formulation and specify the production techniques 
and presence of a robust supply chain.
Encouraging and incentivizing physicians to prescribe 
therapies on the basis of price rather than robust trial data 
undermines the value of the regulatory process and may, 
in the long term, discourage drug manufacturers from 
  investing in research and bringing new drugs to the market. 
In addition to the long-term implications of unlicensed 
drug use, there are also more immediate concerns over the 
monitoring of unlicensed drug safety. It is a legal require-
ment, under EU directive 2001/83, for drug manufacturers 
to design a pharmacovigilance framework to ensure ongo-
ing monitoring of adverse events.5 While the manufacturer 
has a responsibility to record and report adverse events, 
safety reports generated following the unlicensed use of a 
licensed medicine will not be evaluated as part of a formal 
risk management plan. As a result, important emerging 
safety signals may be missed.
The GMC’s proposed revised stance brings to a head 
growing concerns in this area. There is now a need for 
greater understanding of the attitudes towards unlicensed 
prescribing among prescribers themselves. With the aim 
of improving knowledge in the area, Novartis Pharmaceu-
ticals UK Ltd commissioned the Exploring UK Attitudes 
Towards Unlicensed Medicines Use questionnaire-based 
study to explore physicians’ prescribing decisions, priorities 
and attitudes to off-license prescribing and also the public’s 
knowledge of the medication licensing system, awareness of, 
and attitudes to, off-license drug use.
Methods
Data source and patients
A questionnaire-based study was conducted among physi-
cians and members of the general public (hereafter referred 
to throughout as “patients”) to evaluate attitudes and behavior 
around use of unlicensed drugs on the NHS. Separate physi-
cian and patient questionnaires were devised.
Two hundred and forty-nine (n = 249) medical doc-
tors across a wide variety of medical disciplines took part 
in online interviews conducted between 3–10 March 2011. 
The interviews were designed to evaluate prescribers’ 
attitudes and concerns around use of unlicensed drugs and 
the influence that various factors may or may not have on 
prescribing decisions and priorities, as well as assessing the 
impact of the cost-saving challenges currently being faced 
by the NHS.
Patient questionnaires were conducted between 4–7 
March 2011 and involved completion of an online interview 
by adults living in the UK (aged $18 years, n = 500). The 
questions asked were designed to assess knowledge of, and 
concerns around, the use of unlicensed drugs among the 
general population. Information was also captured around 
patient–physician interactions in terms of drug prescribing 
and the degree of trust patients have in their physicians.
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To ensure the participating population was representative 
of the actual population, maximum and minimum quotas were 
set using the online questionnaire software for key population 
demographics. For example, once the maximum number of 
male interviews was met, subsequent questionnaires were 
only conducted in female participants.
Care was taken to ensure no open-ended questions were 
asked as part of the questionnaire. The data analysis was based 
on the numbers captured through the quantitative research. 
No specific treatments or conditions were mentioned in the 
course of the interviews. Figures for general population age, 
sex, and region were weighted where necessary to bring them 
into line with their actual proportions in the population.
Questionnaires
For the purposes of the questionnaire, unlicensed prescribing 
was defined as “prescribing a treatment for a condition for 
which it has no license, is administered via a different route 
and/or where a formulation has been changed”.
Physician questionnaire
The physician questionnaire consisted of 18 questions that 
captured demographic data (see Table 1) and a variety of 
information relating to attitudes to, and concerns around, 
unlicensed drug use (see Appendix 1 for the full physician 
questionnaire).
General knowledge of the implications of unlicensed 
prescribing was gauged by asking physicians how familiar 
they were with the GMC guidelines on unlicensed drug pre-
scribing and how aware they were of their responsibilities if 
they decided to prescribe off-label.
Prescribing priorities were assessed by asking physicians 
to rank (1 high: 4 low) a number of factors and questions 
relating to their prescribing priorities: efficacy, safety, con-
venience (eg, simplicity of dosing regimen) and cost.
General attitudes to prescribing off-label were captured 
through a series of questions around the evidence base they 
believed was necessary to prove the efficacy of a drug (license 
only, guideline endorsement, anecdotal, peer journals) and 
how often they consider the licensed treatment option(s) 
available for a specific condition first (always, sometimes, 
occasionally, rarely, or never). Degree of comfort prescrib-
ing unlicensed treatment was assessed, as were views around 
which circumstances (if any) justify use of an unlicensed 
treatment when a licensed alternative is available and areas 
of concern posed by unlicensed drug prescribing, eg, lack of 
robust safety data, legal risks, lack of pharmacovigilance.
The physicians were posed questions designed to evaluate 
the degree to which budgetary pressures within the NHS may 
affect their prescribing practice in the future and physicians’ 
concerns if they were to come under pressure to prescribe an 
unlicensed therapy over a licensed alternative specifically to 
reduce prescribing costs.
Patient questionnaire
The patient questionnaire consisted of 14 questions that 
captured demographic data (see Table 2) and information 
relating to their understanding of the licensing process and 
perceptions of the use of unlicensed drugs. (See Appendix 2 
for the full patient questionnaire.)
Patients were first asked a number of questions designed 
to capture the patient–physician relationship, eg, the degree 
of trust they place in their physician’s prescribing decisions, 
whether they seek a second opinion when prescribed a 
therapy and whether they view prescribing as a collaborative 
process in which they play a part.
Their knowledge of drug licensing was assessed by asking 
them to indicate their degree of knowledge of the drug regula-
tory process (from “a great deal” to “nothing at all”). They 
were then asked for their level of agreement with a number 
of statements about when medications can be prescribed, eg, 
“Doctors can prescribe any medication they choose to treat a 
condition” and “Medication can be prescribed for a condition 
if it has been approved for that specific condition.”
Table 1 Summary of physician demographics, specialisms and 
prescribing powers
Physician characteristic N (%)
Total 249 (100%)
Geographical distribution of practices
  England 209 (84%)
  Wales 14 (6%)
  Scotland 22 (9%)
  northern Ireland 3 (1%)
Primary/secondary care
  Primary 100 (40%)
  Secondary 149 (60%)
Primary specialty
  General Practice 92 (38%)
  Cardiology 12 (5%)
  Oncology 20 (8%)
  Psychiatry 19 (8%)
  Ophthalmology 19 (8%)
  Anesthesiology 19 (8%)
  neurology 12 (5%)
  Gastroenterology 19 (8%)
  Other 19 (8%)
Prescribing powers
  Yes 249 (100%)
  no 0 (0%)
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As for physicians, patients were asked to rank, in order of 
priority, a number of factors that they believe their physician 
takes into consideration when making prescribing decisions: 
(i) “It works” (ie, efficacy); (ii) “It is safe” (ie, safety); (iii) 
“It is not expensive” (ie, cost); (iv) “It is easy to take or 
administer” (ie, convenience).
To gauge patients’ attitudes towards unlicensed prescrib-
ing, patients were asked questions around how they would 
feel were they prescribed an unlicensed therapy when a 
licensed alternative was available, when they thought it may 
be acceptable to prescribe an unlicensed treatment and how 
concerned they would feel about drug safety if they were 
prescribed an unlicensed therapy.
Results
Demographics
An even mix (50/50) of male and female doctors and patients 
took part in the study, across a wide age range from 18 to 
$55 years (see Tables 1 and 2). 60% of participating physi-
cians worked in secondary care and 40% in primary care; 
all had prescribing rights.6
Familiarity with guidelines and processes
Physicians’ familiarity with the existing GMC 
guidelines
There was limited familiarity with the existing GMC guide-
lines on the use of unlicensed therapies among the physicians 
(only 14% very familiar, 42% somewhat familiar),7 but the 
majority (82%) knew that any problems that occur follow-
ing use of an unlicensed treatment are the responsibility of 
the prescriber.8
Patients’ familiarity with drug licensing
There was limited understanding of the drug licensing process 
in the adults who participated in the study. 69% of patients 
indicated that they have little or no awareness of the drug 
regulatory process and only 8% said they knew a lot about it 
(see Figure 1).9 Around half (53%) of participating patients 
believed medications can only be prescribed for a specific, 
approved condition.10
Evidence base
There was little consensus among physicians on the required 
evidence base to confirm the safety of a therapy. The majority 
(62%) believed national or local guidelines to be sufficient 
proof of safety and 38% of the group felt that recommenda-
tion of drugs by their peers was also a sufficient measure.11
Perceived prescribing influences
The physicians believed the most important consideration 
when prescribing a therapy was its efficacy data (70%), fol-
lowed by its safety (25%). Cost and convenience (eg, dosing 
frequency) were less important considerations.12 Patients also 
believed safety and efficacy to be the most important two 
considerations, but the rank order was reversed with 63% 
believing safety and 30% efficacy to be the greatest prescrib-
ing influences (See Figure 2 and Table 3).13
Patient and physician views differed most greatly on 
the factors that least affect prescribing decisions. Almost 
two-thirds (64%) of patients believed cost to be the least 
important factor when prescribing compared with a lower 
43% of physicians, suggesting physicians may have a greater 
awareness than patients of the role cost plays in prescribing 
decisions (see Table 3).12,13
Table 2 Summary of patient demographics
Patient characteristic N (%)
Total 500 (100%)
Gender (male) 250 (50%)
Age (years)
  18–24 61 (12%)
  25–34 104 (21%)
  35–44 113 (23%)
  45–54 87 (17%)
 $  55 135 (27%)
Geographical distribution
  north East 29 (6%)
  north West 50 (10%)
  Yorkshire and Humberside 50 (10%)
  East Midlands 42 (8%)
  West Midlands 40 (8%)
  East of England 44 (9%)
  London 55 (11%)
  South East 62 (12%)
  South West 47 (9%)
  Wales 30 (6%)
  Scotland 35 (7%)
  northern Ireland 12 (2%)
  Channel Islands 2 (0.4%)
3%
8%
20%
33%
36%
A great deal
Some
A little
Nothing at all
Don’t know
Figure 1 Knowledge of the drug licensing process among patients.9
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Attitudes towards unlicensed prescribing
Physicians
40% of physicians agreed that it is never appropriate to 
prescribe an unlicensed treatment if a licensed treatment is 
available.14 Yet unlicensed prescribing does occur and, when 
questioned, physicians suggested that the main reason for this 
is the absence of a licensed alternative (84% of physicians) 
or because the licensed treatment has failed to work (56% 
of physicians) or has more side effects (40%).15
Only 17% of all physicians questioned indicated they 
would be “very comfortable” prescribing an unlicensed treat-
ment whilst almost one-third (31%) said they would be “not 
very”, or “not at all comfortable” prescribing off-license.16 
Confidence in off-label prescribing was markedly lower 
among primary (7%) compared with secondary care (24%) 
physicians.16 The majority of physicians are at least somewhat 
concerned about the legal risk (76%), lack of robust safety 
data (76%), and safety monitoring (71%) when it comes 
to unlicensed prescribing.17
Patients
From a patient perspective, around one-third (38%) of patients 
felt unlicensed therapy prescribing was acceptable if a licensed 
alternative has already been tried, or if the unlicensed medica-
tion has fewer side effects (37%).18 If there were no alternative 
treatment options available, nearly half (47%) of patients 
would be willing to take an unlicensed medication. A similar 
proportion (43%) would take unlicensed medication if it 
had been proven to be more likely to work for their specific 
  condition.18 Some patients (17%), however, would be dissatis-
fied if prescribed an unlicensed drug over a licensed alternative 
and 14% would refuse or stop taking the medication.19
The role of cost on prescribing behavior
Physicians
The majority (92%) of participating physicians expected 
NHS cost savings to have an impact on future prescribing 
choices.20 Almost half (49%) indicated they were somewhat 
concerned that they might come under pressure to prescribe 
unlicensed therapies for cost saving reasons in the future and 
83% are at least somewhat concerned that cost may become 
the deciding factor in treatment selection.21
Patients
The majority of patients (82%) trust their doctor and similar 
proportions (80%) feel that prescribing decisions are made 
80%
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Factors that MOST influence prescribing
decisions: patient perception/physician view
Figure 2 Summary of factors as perceived by patients and physicians and considered by them as the most influential when making prescribing decisions.12,13
Table 3 Distribution of rank scoring across perceived prescribing influences, split by patient- and physician-perceived views12,13
Rank score of importance Safety Efficacy Convenience and ease of administration Cost
Patient perception
Most important 1 63% 30% 3% 4%
↓
2 29% 61% 5% 5%
3 4% 5% 64% 27%
Least important 4 4% 3% 29% 64%
Physician perception
Most important 1 25% 70% 2% 3%
↓
2 64% 25% 4% 7%
3 8% 2% 43% 46%
Least important 4 3% 2% 52% 43%
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collaboratively between themselves and their physician.22 
Yet, this trust and collaborative relationship could be chal-
lenged if cost becomes a driver of prescribing decisions; 
81% of patients expressed at least some concern (38% were 
“very concerned”) about safety if prescribed an unlicensed 
medication over a licensed medication specifically because 
it is less costly (see Figure 4).23
Discussion
This UK-based questionnaire study suggests real concern 
around the safety and pharmacovigilance issues associated 
with unlicensed drug prescribing. Eighty-one percent (81%) 
of patients expressed at least some concern about safety if 
prescribed an unlicensed treatment and the majority (76%) 
of physicians were at least somewhat concerned about the 
legal risks, lack of robust safety data, and safety monitoring 
of unlicensed prescribing.17,23 Only 17% of physicians indi-
cated they would be very comfortable to prescribe unlicensed 
therapy over a licensed alternative.16
UK patients currently place a high degree of trust in their 
physicians’ prescribing decisions and the majority believe 
prescribing decisions are made collaboratively between 
themselves and their physician. Yet patients can only chal-
lenge unlicensed drug prescribing if they are aware of drug 
licensing issues and over two-thirds (69%) of patients have 
little or no awareness of the drug regulatory process.9
Across both patients and physicians, cost was perceived 
to be the least important factor when deciding whether to 
prescribe an unlicensed therapy when a licensed alternative 
was available. However, a lower percentage of physicians 
(compared with patients) ranked it as the least important fac-
tor, perhaps suggesting a greater awareness among physicians 
of the influence budgetary pressures currently play.12,13 This 
interpretation is supported by the high proportion (92%) of 
physicians who expect cost to become an increasingly impor-
tant factor when prescribing and the high levels of concern 
(83% of physicians at least somewhat concerned) that cost 
will become the deciding factor.20,21
The strengths of this study include the large, geographi-
cally diverse patient population and the multidisciplinary 
nature of the participating physicians. No drugs were men-
tioned in the course of the patient or physician questioning 
allowing objective opinions to be captured. Study limita-
tions that could be resolved in a larger evaluation of this 
kind include the lack of data from physicians in any one 
specialism, geographical location, or age group to compare 
differing trends in physician response by age, geography, 
and specialism.
In conclusion, there is little patient knowledge of the 
drug licensing process and limited physician familiarity with 
the GMC guidance on unlicensed drug prescribing. Patients 
and physicians agreed that safety and efficacy are the most 
important factors to consider when making prescribing deci-
sions and unlicensed prescribing, on the basis of cost, raised 
concerns for both groups. The current environment within the 
NHS, however, means a high proportion of physicians are 
concerned that cost pressures on prescribing will continue 
to increase and may become the deciding factor. A larger 
study of this sort in the future would allow further analysis of 
predictors of physician attitudes and an evaluation of whether 
physicians’ current concerns become a reality and the effect 
this may have on the patient–physician relationship.
Acknowledgments/disclosure
This study was conducted by KRC Research, funded by 
Novartis Pharmaceuticals UK Ltd, and no specific treatments 
or conditions were mentioned or discussed. This publica-
tion was authored independently and has been reviewed by 
  Novartis. The author has no conflicts of interest to declare.
90%
81%
13%
6%
80%
70%
60%
50%
40%
30%
20%
10%
0%
P
e
r
c
e
n
t
 
o
f
 
p
a
t
i
e
n
t
s
At least somewhat
concerned
Not very/not at all
concerned
Don’t know
Patient concern over cost-driven decision to
prescribe unlicensed medication
Figure 4 Aggregated distribution of concern if the patient’s physician prescribed 
them an unlicensed therapy over a licensed alternative because of cost reasons.23
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
P
e
r
c
e
n
t
 
o
f
 
p
h
y
s
i
c
i
a
n
s
At least somewhat concerned Not very/not at all concerned
Attitudes to the lack of pharmacovigilance
programmes to monitor unlicensed therapy use
29%
70%
Total PrimaryS econdary
Figure  3  Level of concern among physicians over absence of pharmacovigilance 
programs for unlicensed therapies, split by place of work (primary/secondary care).24
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
32
ChisholmInternational Journal of General Medicine 2012:5
References
1.  General Medical Council. Guidelines on Good practice in prescribing 
medicines – guidance for doctors. September 2008. Available at: http://
www.gmc-uk.org/guidance/ethical_guidance/prescriptions_faqs.asp#9. 
Last accessed October 14, 2011.
2.  General Medical Council. Good practice in prescribing and managing 
medicines and devices – Draft for consultation. Available at: http://www.
gmc-uk.org/Good_practice_prescribing_consultation_draft_FINAL.
pdf_40006888.pdf. Last accessed November 11, 2011.
3.  Department of Trade and Industry. European Product Liability Directive 
and Part 1 Consumer Protection Act 1987. Available at: http://www.
legislation.gov.uk/ukpga/1987/43/pdfs/ukpga_19870043_en.pdf. Last 
accessed November 9, 2011.
4.  British Medical Association and NHS Employers. QOF Quality and 
Productivity (QP) Indicators. May 2011. Available at: http://www.
nhsemployers.org/SiteCollectionDocuments/QP_supplementary_guid-
ance_and_FAQs_bt270511.pdf. Last accessed November 1, 2011.
5.  European Parliament and the Council. Directive 2001/83/EC of the 
European Parliament of the Council of November 6, 2001 on the 
  Community Code Relating to Medicinal Products for Human Use. 
  Available at: http://www.emea.europa.eu/docs/en_GB/document_library/
Regulatory_and_procedural_guideline/2009/10/WC500004481.pdf. Last 
accessed November 2, 2011.
6.  KRC Unlicensed Medicines Use Survey (prescriber arm) conducted 
March 2011. 
7.  Q10 KRC Unlicensed Medicines Use Survey (prescriber arm) con-
ducted March 2011.
8.  Q11 KRC Unlicensed Medicines Use Survey (prescriber arm) con-
ducted March 2011.
9.  Q7 KRC Unlicensed Medicines Use Survey (general public arm) con-
ducted March 2011.
  10.  Q6 KRC Unlicensed Medicines Use Survey (general public arm) 
conducted March 2011.
  11.  Q2 KRC Unlicensed Medicines Use Survey (prescriber arm) con-
ducted March 2011.
  12.  Q1 KRC Unlicensed Medicines Use Survey (prescriber arm) con-
ducted March 2011. 
  13.  Q8 KRC Unlicensed Medicines Use Survey (general public arm) 
conducted March 2011.
  14.  Q6 KRC Unlicensed Medicines Use Survey (prescriber arm) con-
ducted March 2011.
  15.  Q5 KRC Unlicensed Medicines Use Survey (prescriber arm) con-
ducted March 2011. 
  16.  Q4 KRC Unlicensed Medicines Use Survey (prescriber arm) con-
ducted March 2011.
  17.  Q7–9 KRC Unlicensed Medicines Use Survey (prescriber arm) con-
ducted March 2011.
  18.  Q9 KRC Unlicensed Medicines Use Survey (general public arm) 
conducted March 2011.
  19.  Q10 KRC Unlicensed Medicines Use Survey (general public arm) 
conducted March 2011.
  20.  Q12 KRC Unlicensed Medicines Use Survey (prescriber arm) con-
ducted March 2011. 
  21.  Q13–15 KRC Unlicensed Medicines Use Survey (prescriber arm) 
conducted March 2011.
  22.  Q4–7 KRC Unlicensed Medicines Use Survey (general public arm) 
conducted March 2011.
  23.  Q11 KRC Unlicensed Medicines Use Survey (general public arm) 
conducted March 2011.
  24.  Q9 KRC Unlicensed Medicines Use Survey (prescriber arm) con-
ducted March 2011.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
33
Attitudes towards unlicensed medicine use in the UKInternational Journal of General Medicine 2012:5
Appendix  
Novartis study: exploring UK attitudes towards licensed medicines use 
FINAL
Parameters
Recruitment criteria and sample stratification:
•	 Physicians (medical doctors) who have prescribing responsibilities – 200 interviews
•	 General population (age 18+ years) – 500 interviews
Questionnaire length:
•	 5-minute questionnaire (generally allows for 10–15 question items)
Method:
•	 Online (opted-in panels)
Objectives:
•	 Determine whether physicians are comfortable prescribing unlicensed drugs, what factors determine their prescribing 
behavior, whether they have concerns about the use of unlicensed drugs, and whether they expect the NHS cost-saving 
drive to affect their prescribing habits.
•	 Establish whether the general public have concerns about, or even familiarity with, unlicensed drugs, and their reported 
interactions with their physician when it comes to prescriptions.
Introduction
Thank you for participating in this brief survey. This survey is strictly for research purposes, and should take no more 
than 10 minutes of your time. It is not intended to promote the sale of any product or device, and you will not be con-
tacted for marketing purposes as a result of participating. Your responses will be kept confidential and anonymous, and 
nothing you say will be attributed to you personally.
Appendix 1
Physician survey
We are now being asked to pass on to our client, details of adverse events that are mentioned during the course of market 
research. Although all your responses will, of course, be treated in confidence and anonymously, should you raise during 
the interview an adverse event in a specific patient, we will need to report this, even if it has already been reported by you 
directly to the company or the regulatory authorities using the MHRA’s ‘Yellow Card’ system.
In such a situation, you will be asked whether or not you are willing to waive the confidentiality given to you under the 
Market Research Code of Conduct specifically in relation to that adverse event. Everything else you mention during the course 
of the interview will continue to remain confidential, and you will still have the option to remain anonymous if you so wish.
Are you happy to proceed on this basis?
Yes – Continue
No – Thank you and close
First, some questions to confirm that you qualify for the study:
Physician screening
1.  Where do you practice?
  England......................................................................................................................................................................... 1
  Wales ............................................................................................................................................................................ 2
  Scotland ........................................................................................................................................................................ 3
  Northern Ireland ........................................................................................................................................................... 4
  None of these  .........................................................................................................................................[TERMINATE]
2.  Do you currently have prescribing responsibilities?
  Yes   ................................................................................................................................................................................ 1
  No ..........................................................................................................................................................[TERMINATE]
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3.  Are you involved in primary or secondary care?
  Primary ......................................................................................................................................................................... 1
  Secondary ..................................................................................................................................................................... 2
In the survey below we will be asking for your opinion on scenarios related to prescribing and the use of unlicensed 
treatments. When referring to a treatment being unlicensed, we will be using the following definition:
Without a marketing authorization (unlicensed) in the UK for a specific condition or if used with a variation in its 
licensed formulation or administration.
Throughout this survey, we understand that there are some difficult questions or grey areas. Please answer all questions 
to the best of your ability.
Physician main survey
4.  Below is a list of factors that you may or may not consider when selecting a treatment to prescribe for a specific   condition. 
In general, how important are each of the following factors when prescribing a treatment? Please rank each of the factors 
below from 1 to 4, where 1 means it is the most important, 2 is the second most important, and so on. You can only use 
each number from 1 to 4 once. [RANDOMIZE ORDER OF ITEMS]
Note: We understand that the factors below are not the only ones to be considered. However, please answer to the best 
of your ability based on the factors listed below.
  The proven efficacy of the treatment for that condition  ...................................................................................... _____
  The proven safety profile of the treatment for that condition ............................................................................... _____
  The treatment cost ................................................................................................................................................ _____
  The convenience of the treatment (eg, once daily dosing) ................................................................................... _____
  Do not agree with any of the above .............................................................................................................................. 9
5.  When considering the safety of the treatments you might prescribe for a particular condition, with which of the following 
statements do you agree? (MULTIPLE RESPONSES ACCEPTED)
    Only a license for use in the specific condition for which I am prescribing treatment provides sufficient evidence of 
safety ............................................................................................................................................................................ 1
  A license for use in any condition provides sufficient evidence of safety  .................................................................... 2
    National or local prescribing guidelines (including NICE) provide sufficient evidence of safety, regardless of licensing 
 ...................................................................................................................................................................................... 3
    Peer recommendation (including in journals) or personal experience provides sufficient evidence of safety, regardless 
of licensing ................................................................................................................................................................... 4
    I do not agree with any of these statements (ACCEPT NO OTHER RESPONSES) ....................................................  
 ...................................................................................................................................................................................... 8
  Not sure (ACCEPT NO OTHER RESPONSES) ......................................................................................................... 9
6.  When you come to prescribing, how often do you consider the licensed treatment option(s) available for the specific 
condition first?
  Always .......................................................................................................................................................................... 1
  Sometimes .................................................................................................................................................................... 2
  Occasionally ................................................................................................................................................................. 3
  Rarely ........................................................................................................................................................................... 4
  Never ............................................................................................................................................................................ 5
  Don’t know ................................................................................................................................................................... 9
7.  Generally speaking, please indicate how comfortable you are prescribing an ‘unlicensed’ treatment (prescribing a 
treatment for a condition for which it has no license, is administered via a different route and/or formulation has been 
changed).
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  Very comfortable .......................................................................................................................................................... 1
  Somewhat comfortable ................................................................................................................................................. 2
  Not very comfortable ................................................................................................................................................... 3
  Not at all comfortable  ................................................................................................................................................... 4
  Don’t know ................................................................................................................................................................... 9
  8. In your opinion, which of the following, if any, do you believe are good reasons to select an unlicensed treatment 
over a licensed treatment for a specific condition? Please select all that apply. [RANDOMIZE. ACCEPT MULTIPLE 
RESPONSES.]
  The unlicensed treatment is less expensive .................................................................................................................. 1
  The unlicensed treatment has fewer side effects .......................................................................................................... 2
  The licensed treatment has been tried and did not work .............................................................................................. 3
  There is no licensed alternative .................................................................................................................................... 4
  None of these  ................................................................................................................................................................ 8
  Don’t know ................................................................................................................................................................... 9
  9. To what extent do you agree or disagree with the following statement? [ACCEPT SINGLE RESPONSE.]
It is never appropriate to prescribe an unlicensed treatment if a licensed treatment is available
  Strongly agree .............................................................................................................................................................. 1
  Somewhat agree ........................................................................................................................................................... 2
  Somewhat disagree ....................................................................................................................................................... 3
  Strongly disagree .......................................................................................................................................................... 4
  Don’t know ................................................................................................................................................................... 9
To what extent are you concerned with each of the following when it comes to prescribing unlicensed medications? 
(RANDOMIZE)
Very  
concerned
Somewhat  
concerned
Not very  
concerned
Not at all  
concerned
Don’t   
know
10. That robust safety data are available only  
for licensed conditions, and not always  
available for unlicensed conditions.
1 2 3 4 9
11. That prescribing unlicensed treatments  
could pose legal risks.
1 2 3 4 9
12. That treatment safety monitoring 
(pharmacovigilance) programmes are  
only in place for licensed conditions,  
and not for unlicensed conditions.
1 2 3 4 9
13. Before today, how familiar would you say you were with the following GMC guidelines regarding prescribing unlicensed 
treatments?
  “An unlicensed drug should not be used in a condition where a licensed drug is available. When an unlicensed medicine is 
used, it raises questions on how reporting, interpretation, and the management of adverse events will be undertaken”
  Very familiar  ................................................................................................................................................................. 1
  Somewhat familiar ....................................................................................................................................................... 2
  Not very familiar .......................................................................................................................................................... 3
  Not at all familiar ......................................................................................................................................................... 4
  Don’t know ................................................................................................................................................................... 9
14. Who, if anyone, do you think would be held responsible if a problem occurred following the use of an unlicensed treat-
ment? Please select all that apply. [RANDOMIZE. ACCEPT MULTIPLE RESPONSES.]
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  The individual prescriber  .............................................................................................................................................. 1
  The patient .................................................................................................................................................................... 2
  The PCT manager or hospital trust  ............................................................................................................................... 3
  The lead physician responsible for a patient s care ...................................................................................................... 4
  The hospital pharmacist  ................................................................................................................................................ 5
  None of these  ................................................................................................................................................................ 7
  No one would be held responsible  ................................................................................................................................ 8
  Don’t know ................................................................................................................................................................... 9
In the current economic climate, the National Health Service is being challenged to identify areas where cost savings 
can be found. Within this, expenditure on drugs has been identified as one route to reducing annual NHS expenditure.
15. What impact, if any, do you think the current NHS focus on cost saving will personally have on your prescribing choices:
  It will have a significant impact on my prescribing choices  ......................................................................................... 1
  It will have some impact on my prescribing choices  .................................................................................................... 2
  It will have no impact at all .......................................................................................................................................... 3
  Don’t know ................................................................................................................................................................... 9
Taking into account the aforementioned anticipated changes to the NHS expenditure on drugs, to what extent are you 
concerned with each of the following when it comes to using unlicensed medication? (RANDOMIZE)
Very  
concerned
Somewhat  
concerned
Not very  
concerned
Not at all  
concerned
Don’t  
know
16. Unlicensed medicines might be 
increasingly selected over licensed 
medicines for cost-saving reasons.
1 2 3 4 9
17. Cost might become the deciding factor 
in treatment selection.
1 2 3 4 9
18. I might come under pressure to prescribe 
an unlicensed treatment for a specific 
condition, purely for cost reasons.
1 2 3 4 9
Appendix 2
General population survey
Thank you for participating in this brief survey. This survey is strictly for research purposes, and should take no more than 
10 minutes of your time. It is not intended to promote the sale of any product or device, and you will not be contacted for 
marketing purposes as a result of participating. Your responses will be kept confidential and anonymous, and nothing you 
say will be attributed to you personally.
It is required that we pass on details of adverse events that are mentioned during the course of market research. (By “adverse 
events”, we mean side effects or other consequences of your treatment or medication.) Although all your responses will, of course, 
be treated in confidence and anonymously, should you mention an adverse event during the interview, we will need to report 
this, even if it has already been reported by you directly to your physician, to the manufacturer, or to any regulatory authority.
In such a situation you will be asked whether or not you are willing to waive the confidentiality given to you under the Mar-
ket Research Code of Conduct specifically in relation to that adverse event. Everything else you mention during the course of 
the interview will continue to remain confidential, and you will still have the option to remain anonymous if you so wish.
Are you happy to proceed on this basis?
Yes – Continue
No – Thank you and close
First, some questions to confirm that you qualify for the study.
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Screening (needed for eligibility and also quotas)
19. Are you…?
  Male  .............................................................................................................................................................................. 1
  Female .......................................................................................................................................................................... 2
20. What is your current age? [TERMINATE IF NOT AGE 18+.]
Enter your age here: ...................................................................................................................................__ __ years old
21. Where do you live?
  North East  ..................................................................................................................................................................... 1
  North West .................................................................................................................................................................... 2
  Yorkshire and Humberside  ............................................................................................................................................ 3
  East Midlands ............................................................................................................................................................... 4
  West Midlands .............................................................................................................................................................. 5
  East of England ............................................................................................................................................................ 6
  London ......................................................................................................................................................................... 7
  South East  ..................................................................................................................................................................... 8
  South West .................................................................................................................................................................... 9
  Wales .......................................................................................................................................................................... 10
  Scotland ...................................................................................................................................................................... 11
  Northern Ireland ......................................................................................................................................................... 12
  Channel Islands .......................................................................................................................................................... 13
  None of these  .........................................................................................................................................[TERMINATE]
General population main survey
To what extent do you agree or disagree with each of the following statements? [RANDOMIZE]
Completely  
agree
Somewhat  
agree
Somewhat  
disagree
Completely  
disagree
Don’t   
know
22. I generally trust the decisions my doctor  
makes without question.
1 2 3 4 9
23. I view making decisions with my doctor  
as a collaborative process.
1 2 3 4 9
24. I always carry out my own research  
on anything my doctor prescribes me.
1 2 3 4 9
25. I always seek a second opinion before  
following the doctor’s instructions.
1 2 3 4 9
26. When your doctor prescribes medication to you, how often do you ask questions about the medication?
  Frequently  ..................................................................................................................................................................... 1
  Often ............................................................................................................................................................................. 2
  Rarely ........................................................................................................................................................................... 3
  Never ............................................................................................................................................................................ 4
  Don’t know ................................................................................................................................................................... 8
  My doctor never prescribes medication to me ............................................................................................................. 9
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27. Which of the following comes closest to your opinion, to the best of your knowledge? (RANDOMIZE FIRST   
TWO OPTIONS)
Doctors can prescribe any medication they choose to treat a condition .......................................................................... 1
  Medication can only be prescribed for a condition if it has been approved for that specific condition .............................  
 .......................................................................................................................................................................................... 2
Neither of these ................................................................................................................................................................ 8
Don’t know ....................................................................................................................................................................... 9
To receive a license for use in a particular condition, medicines must undergo strict regulatory processes. Once licensed, 
they continue to be subject to the UK’s safety monitoring and reporting procedures.
If a medicine is used outside of its license (for a medical condition for which it doesn’t have a license), it is not subject 
to the same robust safety procedures.
28. How much would you say you know about the regulatory process that all medications need to go through to gain a 
license to be prescribed to patients?
  A great deal .................................................................................................................................................................. 1
  Some ............................................................................................................................................................................. 2
  A little ........................................................................................................................................................................... 3
  Nothing at all ................................................................................................................................................................ 4
  Don’t know ................................................................................................................................................................... 9
29. When your doctor prescribes medication for you, what do you think are the most important factors about the medication 
that your doctor should consider.
Please rank each of the factors below from 1 to 4, where 1 means it is the most important, 2 is the second most important, 
and so on. You can only use each number from 1 to 4 once. [RANDOMIZE ORDER OF ITEMS]
  It works  ................................................................................................................................................................ _____
  It is safe ................................................................................................................................................................ _____
  It is not expensive ................................................................................................................................................. _____
  It is easy to take or administer  .............................................................................................................................. _____
30. To the best of your knowledge, in which of the following situations would you think it acceptable for a doctor to prescribe 
you with a medication that wasn’t approved for a particular condition you might have (unlicensed) rather than medica-
tion licensed and approved for use for the condition (licensed)? Please select all that apply. [RANDOMIZE. ACCEPT 
MULTIPLE RESPONSES.]
  If it is less expensive..................................................................................................................................................... 1
  If the licensed medication has been tried first .............................................................................................................. 2
  If there were no alternative treatment options .............................................................................................................. 3
  If it is proven to be more likely to work for me than the licensed medication ............................................................. 4
  If it is proven to have fewer side effects than the licensed medication ........................................................................ 5
  None of these  ................................................................................................................................................................ 8
  Don’t know ................................................................................................................................................................... 9
31. If you were prescribed an unlicensed treatment when a licensed treatment is available, how would you feel? Please select 
all that apply. (RANDOMIZE.)
  I would not have a problem with it – I trust my doctor ................................................................................................ 1
  I would ask some follow up questions to learn more, then make a decision ............................................................... 2
  I would be dissatisfied with my doctor ......................................................................................................................... 3
  I would stop taking or refuse to take the treatment immediately ................................................................................. 4
  None of these  ................................................................................................................................................................ 8
  Don’t know ................................................................................................................................................................... 9
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
39
Attitudes towards unlicensed medicine use in the UKInternational Journal of General Medicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-general-medicine-journal
The International Journal of General Medicine is an international, 
peer-reviewed open-access journal that focuses on general and internal 
medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat-
ment protocols. The journal is characterized by the rapid reporting of 
reviews, original research and clinical studies across all disease areas. 
A key focus is the elucidation of disease processes and management 
protocols resulting in improved outcomes for the patient.The manu-
script management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of General Medicine 2012:5
32. If your doctor prescribed you a treatment that is not licensed for your specific condition, specifically because it costs less 
that a licensed alternative, how concerned would you be about its safety?
  Very concerned ............................................................................................................................................................. 1
  Somewhat concerned  .................................................................................................................................................... 2
  Not very concerned ...................................................................................................................................................... 3
  Not at all concerned ..................................................................................................................................................... 4
  Don’t know ................................................................................................................................................................... 9
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